Molecular glue degrader for tumor treatment
Targeted Protein Degradation (TPD) represented by Proteolysis-Targeting Chimeras (PROTAC) is the frontier field in the research and development of antitumor therapy, in which oral drug HP518 Receives FDA Proceed Authorization for its IND Application for Prostate Cancer Treatment. Recently, molecular...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-12-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1512666/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841560967036534784 |
|---|---|
| author | Yuhan Hu Yan Yan Jiehao Wang Jiangxue Hou Quande Lin |
| author_facet | Yuhan Hu Yan Yan Jiehao Wang Jiangxue Hou Quande Lin |
| author_sort | Yuhan Hu |
| collection | DOAJ |
| description | Targeted Protein Degradation (TPD) represented by Proteolysis-Targeting Chimeras (PROTAC) is the frontier field in the research and development of antitumor therapy, in which oral drug HP518 Receives FDA Proceed Authorization for its IND Application for Prostate Cancer Treatment. Recently, molecular glue, functioning via degradation of the target protein is emerging as a promising modality for the development of therapeutic agents, while exhibits greater advantages over PROTAC, including improved efficiency, resistance-free properties, and the capacity to selectively target “undruggable” proteins. This marks a revolutionary advancement in the landscape of small molecule drugs. Given that molecular glue research is still in its early stage, we summarized the mechanisms of molecular glue, the promising drugs in clinical trials and diverse feasible design strategies for molecular glue therapeutics. |
| format | Article |
| id | doaj-art-69b79d6e2cb74a5593b7dd1c9fce8fd4 |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-69b79d6e2cb74a5593b7dd1c9fce8fd42025-01-03T08:19:18ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2024-12-011410.3389/fonc.2024.15126661512666Molecular glue degrader for tumor treatmentYuhan Hu0Yan Yan1Jiehao Wang2Jiangxue Hou3Quande Lin4Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, ChinaDepartment of Infectious Diseases, Zhoukou Central Hospital, Zhoukou, ChinaDepartment of Gastroenterology, Zhengzhou First People's Hospital, Zhengzhou, ChinaDepartment of Hematology, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, ChinaDepartment of Hematology, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, ChinaTargeted Protein Degradation (TPD) represented by Proteolysis-Targeting Chimeras (PROTAC) is the frontier field in the research and development of antitumor therapy, in which oral drug HP518 Receives FDA Proceed Authorization for its IND Application for Prostate Cancer Treatment. Recently, molecular glue, functioning via degradation of the target protein is emerging as a promising modality for the development of therapeutic agents, while exhibits greater advantages over PROTAC, including improved efficiency, resistance-free properties, and the capacity to selectively target “undruggable” proteins. This marks a revolutionary advancement in the landscape of small molecule drugs. Given that molecular glue research is still in its early stage, we summarized the mechanisms of molecular glue, the promising drugs in clinical trials and diverse feasible design strategies for molecular glue therapeutics.https://www.frontiersin.org/articles/10.3389/fonc.2024.1512666/fullmolecular glue degradertumordesign strategiesmechanismclinical trials |
| spellingShingle | Yuhan Hu Yan Yan Jiehao Wang Jiangxue Hou Quande Lin Molecular glue degrader for tumor treatment Frontiers in Oncology molecular glue degrader tumor design strategies mechanism clinical trials |
| title | Molecular glue degrader for tumor treatment |
| title_full | Molecular glue degrader for tumor treatment |
| title_fullStr | Molecular glue degrader for tumor treatment |
| title_full_unstemmed | Molecular glue degrader for tumor treatment |
| title_short | Molecular glue degrader for tumor treatment |
| title_sort | molecular glue degrader for tumor treatment |
| topic | molecular glue degrader tumor design strategies mechanism clinical trials |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1512666/full |
| work_keys_str_mv | AT yuhanhu moleculargluedegraderfortumortreatment AT yanyan moleculargluedegraderfortumortreatment AT jiehaowang moleculargluedegraderfortumortreatment AT jiangxuehou moleculargluedegraderfortumortreatment AT quandelin moleculargluedegraderfortumortreatment |